JP2017524734A5 - - Google Patents

Download PDF

Info

Publication number
JP2017524734A5
JP2017524734A5 JP2017521031A JP2017521031A JP2017524734A5 JP 2017524734 A5 JP2017524734 A5 JP 2017524734A5 JP 2017521031 A JP2017521031 A JP 2017521031A JP 2017521031 A JP2017521031 A JP 2017521031A JP 2017524734 A5 JP2017524734 A5 JP 2017524734A5
Authority
JP
Japan
Prior art keywords
amino
methyl
carbonyl
thienyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017521031A
Other languages
English (en)
Japanese (ja)
Other versions
JP6603712B2 (ja
JP2017524734A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/038712 external-priority patent/WO2016004136A1/en
Publication of JP2017524734A publication Critical patent/JP2017524734A/ja
Publication of JP2017524734A5 publication Critical patent/JP2017524734A5/ja
Application granted granted Critical
Publication of JP6603712B2 publication Critical patent/JP6603712B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017521031A 2014-07-01 2015-06-30 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物 Active JP6603712B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462019756P 2014-07-01 2014-07-01
US62/019,756 2014-07-01
US201562185678P 2015-06-28 2015-06-28
US62/185,678 2015-06-28
PCT/US2015/038712 WO2016004136A1 (en) 2014-07-01 2015-06-30 Heteroaryl compounds useful as inhibitors of sumo activating enzyme

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019187426A Division JP2020023538A (ja) 2014-07-01 2019-10-11 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物

Publications (3)

Publication Number Publication Date
JP2017524734A JP2017524734A (ja) 2017-08-31
JP2017524734A5 true JP2017524734A5 (enExample) 2019-07-11
JP6603712B2 JP6603712B2 (ja) 2019-11-06

Family

ID=55019950

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017521031A Active JP6603712B2 (ja) 2014-07-01 2015-06-30 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物
JP2019187426A Withdrawn JP2020023538A (ja) 2014-07-01 2019-10-11 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物
JP2021131914A Pending JP2021178869A (ja) 2014-07-01 2021-08-13 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物
JP2023191459A Withdrawn JP2024012558A (ja) 2014-07-01 2023-11-09 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019187426A Withdrawn JP2020023538A (ja) 2014-07-01 2019-10-11 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物
JP2021131914A Pending JP2021178869A (ja) 2014-07-01 2021-08-13 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物
JP2023191459A Withdrawn JP2024012558A (ja) 2014-07-01 2023-11-09 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物

Country Status (39)

Country Link
US (6) US9683003B2 (enExample)
EP (3) EP3164130B1 (enExample)
JP (4) JP6603712B2 (enExample)
KR (1) KR102491125B1 (enExample)
CN (1) CN106999479B (enExample)
AU (1) AU2015284135B2 (enExample)
BR (1) BR112016030787B1 (enExample)
CA (1) CA2953132C (enExample)
CL (1) CL2016003398A1 (enExample)
CR (1) CR20170021A (enExample)
CY (1) CY1122808T1 (enExample)
DK (1) DK3164130T3 (enExample)
DO (1) DOP2016000339A (enExample)
EA (1) EA034119B1 (enExample)
EC (1) ECSP17006751A (enExample)
ES (1) ES2754359T3 (enExample)
GE (2) GEP20197047B (enExample)
HR (1) HRP20191979T1 (enExample)
HU (1) HUE045748T2 (enExample)
IL (1) IL249820B (enExample)
LT (1) LT3164130T (enExample)
ME (1) ME03574B (enExample)
MX (1) MX376054B (enExample)
MY (1) MY183649A (enExample)
NZ (1) NZ728162A (enExample)
PE (1) PE20170520A1 (enExample)
PH (1) PH12016502595B1 (enExample)
PL (1) PL3164130T3 (enExample)
PT (1) PT3164130T (enExample)
RS (1) RS59474B1 (enExample)
SG (1) SG11201610476VA (enExample)
SI (1) SI3164130T1 (enExample)
SM (1) SMT201900600T1 (enExample)
TN (1) TN2016000581A1 (enExample)
TW (1) TWI680970B (enExample)
UA (1) UA122963C2 (enExample)
UY (1) UY36198A (enExample)
WO (1) WO2016004136A1 (enExample)
ZA (1) ZA201700386B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116534C2 (uk) 2012-02-17 2018-04-10 Мілленніум Фармасьютікалз, Інк. Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту
CN104684559A (zh) 2012-08-03 2015-06-03 米伦纽姆医药公司 针对Uba6的吲哚取代的吡咯并嘧啶基抑制剂
BR112016030787B1 (pt) 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso
US10465447B2 (en) 2015-03-12 2019-11-05 Baker Hughes, A Ge Company, Llc Cutting elements configured to mitigate diamond table failure, earth-boring tools including such cutting elements, and related methods
TWI730980B (zh) 2015-08-26 2021-06-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
BR112019006414A2 (pt) 2016-10-03 2019-06-25 Janssen Pharmaceutica Nv análogos de carbanucleosídeos de sistema de anel monocíclico e bicíclico substituídos para uso como inibidores de prmt5
SG11201907607VA (en) 2017-02-27 2019-09-27 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
US10400517B2 (en) 2017-05-02 2019-09-03 Baker Hughes, A Ge Company, Llc Cutting elements configured to reduce impact damage and related tools and methods
JP2020534331A (ja) 2017-09-21 2020-11-26 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. ((1s,2s,4r)−4−{4−[(1s)−2,3−ジヒドロ−1h−インデン−1−イルアミノ]−7h−ピロロ[2,3−d]ピリミジン−7−イル}−2−ヒドロキシシクロペンチル)メチルスルファメートの共結晶形態、その製剤及び使用
MX2020005944A (es) 2017-12-08 2020-08-24 Janssen Pharmaceutica Nv Analogos espirobiciclicos novedosos.
EP3768685A1 (en) 2018-03-23 2021-01-27 Takeda Pharmaceutical Company Limited Sting modulator compounds with sulfamate linkages, and methods of making and using
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
US12097199B2 (en) 2018-07-09 2024-09-24 Takeda Pharmaceutical Company Limited Administration of SUMO-activating enzyme inhibitor and anti-CD20 antibodies
US10570668B2 (en) 2018-07-27 2020-02-25 Baker Hughes, A Ge Company, Llc Cutting elements configured to reduce impact damage and mitigate polycrystalline, superabrasive material failure earth-boring tools including such cutting elements, and related methods
CN109354569A (zh) * 2018-11-27 2019-02-19 常州大学 一种1,3-二溴-4-氟苯的制备方法
US20220133884A1 (en) * 2019-02-26 2022-05-05 Millennium Pharmaceuticals, Inc. Compounds useful as adjuvants
US12419890B2 (en) 2019-02-27 2025-09-23 Takeda Pharmaceutical Company Limited Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用prmt5抑制劑治療癌症之方法
EP3782702A1 (en) * 2019-08-21 2021-02-24 AC BioScience SA Compounds and use thereof for the treatment of infectious diseases and cancer
CN112402608B (zh) * 2020-11-30 2021-09-07 深圳先进技术研究院 5-烷氧基吲哚-3-乙烯基喹啉盐作为靶向可迁移光敏剂的应用
US12636365B2 (en) 2019-12-04 2026-05-26 Shenzhen Institutes Of Advanced Technology Mitochondrion/ribonucleic acid-targeted and migratable photosensitized probe and application thereof
WO2021203001A1 (en) * 2020-04-03 2021-10-07 Millennium Pharmaceuticals, Inc. Method of treating patients infected with a viral infection with an inhibitor of small ubiquitin like modifier activating enzyme
BR112022023137A2 (pt) * 2020-05-15 2023-02-07 Takeda Pharmaceuticals Co Administração de inibidor de enzima de ativação de sumo e anticorpos anti-cd38
US12134938B2 (en) 2021-02-05 2024-11-05 Baker Hughes Oilfield Operations Llc Cutting elements for earth-boring tools, methods of manufacturing earth-boring tools, and related earth-boring tools
CN113173852B (zh) * 2021-04-26 2022-07-12 深圳市华先医药科技有限公司 二氟丙二酸酯类化合物的制备方法
WO2023073645A1 (en) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
US11920409B2 (en) 2022-07-05 2024-03-05 Baker Hughes Oilfield Operations Llc Cutting elements, earth-boring tools including the cutting elements, and methods of forming the earth-boring tools
EP4567027A4 (en) * 2022-08-01 2026-07-15 Jiangsu Hansoh Pharmaceutical Group Co Ltd BICYCLIC INHIBITOR INTERMEDIATE AND METHOD FOR PREPARING IT
JP2025534374A (ja) * 2022-09-30 2025-10-15 ウィゲン・バイオメディシン・テクノロジー・(シャンハイ)・カンパニー・リミテッド Sumo活性化酵素阻害剤としての化合物
CN120112536A (zh) * 2022-11-11 2025-06-06 微境生物医药科技(上海)有限公司 作为sumo活化酶抑制剂的化合物
WO2024110863A1 (en) 2022-11-22 2024-05-30 Takeda Pharmaceutical Company Limited Process and intermediates for preparing ((1r,2s,4r)-4-((5-(4-((r)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl)-5-methylthiophene-2-carbonyl)pyrimidin-4-yl)amino)-2-hydroxycyclopentyl)methyl sulfamate
CN117209449B (zh) * 2023-09-14 2025-11-28 上海毕得医药科技股份有限公司 一种2-(三氟甲基)噻唑类化合物的合成方法
NL2035852B1 (en) 2023-09-21 2025-03-28 Academisch Ziekenhuis Leiden Enhancement of t cell mediated therapies
CN119371416B (zh) * 2024-12-23 2025-05-30 上海达歌生物医药科技有限公司 一种通过氧杂环丁烷开环以构建4-取代异香豆素及其类似物的合成方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
WO1997005132A1 (en) 1995-07-28 1997-02-13 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
WO2003073989A2 (en) 2002-02-28 2003-09-12 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
JP2005525398A (ja) * 2002-04-10 2005-08-25 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ブラジキニン受容体モジュレーターとして有用な新規なヘテロアリールアルキルアミド誘導体
US7527966B2 (en) 2002-06-26 2009-05-05 Transgenrx, Inc. Gene regulation in transgenic animals using a transposon-based vector
US7291603B2 (en) 2002-07-24 2007-11-06 Ptc Therapeutics, Inc. Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
WO2004009610A2 (en) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
KR20050058507A (ko) 2002-09-04 2005-06-16 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
DE60313872T2 (de) 2002-09-04 2008-01-17 Schering Corp. Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
EP1597255A1 (en) 2002-11-13 2005-11-23 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
WO2004087707A1 (en) 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ[1,5−a]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
US20050130974A1 (en) 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors
WO2005051949A1 (ja) 2003-11-26 2005-06-09 Dainippon Sumitomo Pharma Co., Ltd. 新規縮合イミダゾール誘導体
US20050282818A1 (en) 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
WO2006084281A1 (en) 2005-02-04 2006-08-10 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
CN101321759A (zh) 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶化合物
HRP20120786T1 (hr) 2006-02-02 2012-11-30 Millennium Pharmaceuticals, Inc. Inhibitori aktivirajuä†eg enzima e1
ME02789B (me) * 2006-08-08 2011-06-30 Millennium Pharm Inc Jedinjenja heteroarila korisna kao inhibitori e1 aktivirajućih enzima
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
CA2691987C (en) 2007-06-12 2016-08-16 Achaogen, Inc. Antibacterial agents
EP2540727B1 (en) 2007-08-02 2018-07-25 Millennium Pharmaceuticals, Inc. Sulfamoylating reagent
WO2009082691A1 (en) 2007-12-21 2009-07-02 Board Of Regents, University Of Texas System Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010022128A1 (en) 2008-08-20 2010-02-25 Schering Corporation Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734487A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010022121A1 (en) 2008-08-20 2010-02-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010039548A2 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
EP2430026A1 (en) 2009-05-14 2012-03-21 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
NZ623069A (en) 2009-08-17 2015-11-27 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
US9433621B2 (en) 2010-02-18 2016-09-06 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2791738C (en) 2010-03-01 2020-06-09 Gtx, Inc. Aryl imidazolyl compounds for the treatment of cancer
HUE052110T2 (hu) 2010-07-29 2021-04-28 Rigel Pharmaceuticals Inc AMPK-t aktiváló heterociklusos vegyületek és alkalmazásuk
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
MY166889A (en) * 2011-08-24 2018-07-24 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
EP2773207B1 (en) 2011-10-31 2018-03-07 Merck Sharp & Dohme Corp. Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
UA116534C2 (uk) 2012-02-17 2018-04-10 Мілленніум Фармасьютікалз, Інк. Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
WO2015002994A2 (en) * 2013-07-02 2015-01-08 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
US20150087673A1 (en) 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
US10329270B2 (en) 2013-10-21 2019-06-25 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
WO2015110999A1 (en) 2014-01-24 2015-07-30 Piramal Enterprises Limited Ezh2 inhibitors and uses thereof
BR112016030787B1 (pt) 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso

Similar Documents

Publication Publication Date Title
CN115605476B (zh) 取代的三环化合物
JP7860103B2 (ja) 複素環式スピロ化合物及びその使用方法
KR101750667B1 (ko) Syk 억제제
KR101903925B1 (ko) 헤테로아릴 화합물의 합성 및 정제 방법
DE60304718T2 (de) Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
JP6306049B2 (ja) A2aアンタゴニスト特性を有するヘテロビシクロ−置換−[1,2,4]トリアゾロ[1,5−c]キナゾリン−5−アミン化合物
JP5232841B2 (ja) N4−フェニルキナゾリン−4−アミン誘導体の製造方法およびその中間体
KR20210099611A (ko) 헤테로 방향족 유도체 조절제, 이의 제조방법 및 용도
AU2018243770A1 (en) Isoquinolines as inhibitors of HPK1
JP2022502424A5 (enExample)
JP2006521398A (ja) TGFβの二−環式ピリミジン阻害剤
WO2015171527A1 (en) Pyrazolopyridine pyrazolopyrimidine and related compounds
AU2004210855A1 (en) Pyrazoles and methods of making and using the same
JP2005526029A (ja) 細胞増殖が関与する疾患を治療するためのキノリノン誘導体
KR20110039307A (ko) 이미다조피리딘-2-온 유도체
HRP20211483T1 (hr) Derivati 2-(3-(1h-benzo[d]imidazol-1-il)propil)piperidin-3-ola i povezani spojevi kao inhibitori prs za liječenje npr. raka
JP2022502424A (ja) モノアシルグリセロールリパーゼ調節因子
AU2010334591C1 (en) Inhibitors of AKT activity
HU204273B (en) Process fo producing triazolo-benzo- and thieno-triazolo-diazepines and pharmaceutical compositions containing them
WO2022167682A1 (en) Azabicyclic shp2 inhibitors
RU2019108717A (ru) Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов
CA2723279A1 (en) 3-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
CN120897742A (zh) 通过抑制9型磷酸二酯酶增强血清素能致幻药物在治疗或预防某些神经精神障碍中的功效
HUT51486A (en) Process for production of medical compositions containing linearly anellated tricyclic compositions suitable for hindering the aggregation of erotricites
CA3250387A1 (en) Tetrahydropyrido[3,4-D]pyrimidine compounds used as HPK1 inhibitors